Anavex Life Sciences (AVXL)
NASDAQ:AVXL
Want to see AVXL full AI Analyst Report?
AVXL Stock Chart & Stats
$3.64
-$1.39(-10.33%)
At close: 4:00 PM EST
$3.64
-$1.39(-10.33%)
Day’s Range― - ―
52-Week Range$2.61 - $13.99
Previous CloseN/A
Volume1.46M
Average Volume (3M)955.78K
Market Cap
$266.89M
Enterprise Value$115.68M
Total Cash (Recent Filing)$131.75M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.74
Next Earnings
Aug 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.46
Shares Outstanding92,671,760
10 Day Avg. Volume1,057,049
30 Day Avg. Volume955,780
Financial Highlights & Ratios
PEG Ratio-4.26
Price to Book (P/B)8.00
Price to Sales (P/S)0.00
P/FCF Ratio-19.44
Enterprise Value/Market Cap0.43
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.89
Forecast
1Y Price Target
$20.00Price Target Upside449.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.33
Revenue Forecast (FY)$776.00M
Bulls Say, Bears Say
Bulls Say
Financial ResourcesAnavex maintains sufficient cash resources to support operations at the current burn rate, supporting continuation of clinical development without added financing pressure.
Safety ProfileClinical studies reported no significant safety concerns for blarcamesine, including absence of amyloid-related imaging abnormalities, supporting a favorable tolerability profile.
Scientific Validation And VisibilityPlanned scientific presentations and peer-reviewed publications of trial findings will increase awareness and provide independent validation of blarcamesine's clinical effects.
Bears Say
Clinical And Financing RisksKey risks include the possibility of negative clinical results, failure to obtain approvals, challenges launching the drug commercially, setbacks with other candidates, and potential shareholder dilution.
European Approval DelayThe withdrawal of the marketing application for blarcamesine in Europe creates a delay that increases uncertainty around the program's approval prospects and commercial rollout in that market.
Regulatory RequirementsRegulators may require additional clinical studies before granting approval, which could expand development timelines and raise program costs.
Anavex Life Sciences News
AVXL FAQ
What was Anavex Life Sciences’s price range in the past 12 months?
Anavex Life Sciences lowest stock price was $2.61 and its highest was $13.99 in the past 12 months.
What is Anavex Life Sciences’s market cap?
Anavex Life Sciences’s market cap is $266.89M.
When is Anavex Life Sciences’s upcoming earnings report date?
Anavex Life Sciences’s upcoming earnings report date is Aug 11, 2026 which is in 82 days.
How were Anavex Life Sciences’s earnings last quarter?
Currently, no data Available
Is Anavex Life Sciences overvalued?
According to Wall Street analysts Anavex Life Sciences’s price is currently Undervalued.
Does Anavex Life Sciences pay dividends?
Anavex Life Sciences does not currently pay dividends.
What is Anavex Life Sciences’s EPS estimate?
Anavex Life Sciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Anavex Life Sciences have?
Anavex Life Sciences has 92,671,760 shares outstanding.
What happened to Anavex Life Sciences’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Anavex Life Sciences?
Currently, no hedge funds are holding shares in AVXL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Anavex Life Sciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$20.00 (449.45% Upside)
$20.00 (449.45% Upside)
Blogger Sentiment
Bullish
AVXL Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 9.3%
Last 30 Days ▼ 9.3%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-68.36%
12-Months-Change
Fundamentals
Return on Equity
-38.76%
Trailing 12-Months
Asset Growth
7.21%
Trailing 12-Months
Company Description
Anavex Life Sciences
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
AVXL Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a cautiously optimistic tone: the company reports a strong cash position with multi-year runway, notable reductions in burn, positive clinical signals (especially in the AB-clear precision-medicine subgroup) and constructive regulatory engagement with the FDA. However, the CHMP negative opinion, a missed ADCS-ADL endpoint in the original EU submission, and remaining execution and regulatory obligations (including potential confirmatory post-approval studies) are meaningful near-term risks. Overall, positive operational and scientific developments outweigh the regulatory setbacks, but outcomes remain contingent on ongoing reexamination and further regulatory interactions.View all AVXL earnings summariesAVXL Stock 12 Month Forecast
Average Price Target
$20.00
▲(449.45% Upside)
Technical Analysis
Galectin Therapeutics
―
Rocket Pharmaceuticals
―
Cellectis SA
―
Autolus Therapeutics
―
PepGen Inc.
―
Ownership Overview
1.70% Insiders
7.75% Mutual Funds
3.70% Other Institutional Investors
73.06% Public Companies and
Individual Investors